4.5 Article

Persistent Symptoms of Dengue: Estimates of the Incremental Disease and Economic Burden in Mexico

Journal

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
Volume 94, Issue 5, Pages 1085-1089

Publisher

AMER SOC TROP MED & HYGIENE
DOI: 10.4269/ajtmh.15-0896

Keywords

-

Funding

  1. Sanofi Pasteur
  2. Pfizer Institute for Science (Epidemiological Research Fund)
  3. Consejo Nacional de Ciencia y Tecnologia de Mexico, CONACyT (Sectorial Fund for Research on Social Health and Security) [138511]

Ask authors/readers for more resources

Dengue is mostly considered an acute illness with three phases: febrile, critical with possible hemorrhagic manifestations, and recovery. But some patients present persistent symptoms, including fatigue and depression, as acknowledged by the World Health Organization. If persistent symptoms affect a non-negligible share of patients, the burden of dengue will be underestimated. On the basis of a systematic literature review and econometric modeling, we found a significant relationship between the share of patients reporting persisting symptoms and time. We updated estimates of the economic burden of dengue in Mexico, addressing uncertainty in productivity loss and incremental expenses using Monte Carlo simulations. Persistent symptoms represent annually about US$22.6 (95% certainty level [CL]: US$13-US$ 29) million in incremental costs and 28.2 (95% CL: 21.6-36.2) additional disability-adjusted life years per million population, or 13% and 43% increases over previous estimates, respectively. Although our estimates have uncertainty from limited data, they show a substantial, unmeasured burden. Similar patterns likely extend to other dengue-endemic countries.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available